error proof 4
C Difficile Treatment Shows Positive Results in Phase 2 Study
September 5th 2024CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.